Medtronic buys neurovascular tools maker Scientia Vascular for $550M
What's the deal? MedtronicDealroom has a profile for this one. Try Dealroom → has agreed to acquire Scientia Vascular, a Salt Lake City-based maker of neurovascular access tools, for $550 million, with additional undisclosed earn-out and milestone payments possible.
Scientia, which has around 310 employees, was founded by John LippertDealroom has a profile for this one. Try Dealroom →, who serves as its chief technology officer. The deal is expected to close in the first half of Medtronic's fiscal year 2027.
Why now? Scientia makes guidewires and catheters designed to navigate the brain's complex, tortuous blood vessels — the hardware that physicians need before they can even begin treating a stroke or aneurysm.
Medtronic already has a strong neurovascular therapy portfolio but has lacked a leading access line to match. Scientia fills that gap, giving Medtronic a complete procedural toolkit at a moment when stroke treatment — where every second of delayed blood flow destroys brain cells — is under intense clinical and commercial focus.
What could go wrong? The deal is expected to be mildly dilutive to Medtronic's adjusted earnings per share in fiscal year 2027 before turning accretive. Regulatory clearance is still required, and integration of a 310-person specialist firm into a 90,000-employee global corporation carries execution risk. Earn-out structures can also create post-close tension if commercial targets prove hard to hit.
The signal: This acquisition fits a clear pattern in medtech: large device companies are buying smaller specialists to own the full procedural workflow rather than just one step in it.
For Medtronic, adding Scientia means it can sell a physician everything from first access to final treatment in neurovascular cases — a bundling strategy that strengthens its position with hospital systems and reduces the risk of losing a case to a competitor at the access stage.
With stroke incidence rising globally as populations age, neurovascular is one of the sector's most attractive long-term growth categories.
Sources:
Medtronic
PR Newswire
Reuters
Pulse 2.0
Intellectia.ai
Morningstar
NeuroNews International
Cardiovascular Business
J.V.
